Surgery Partners SGRY Q1 2026 Earnings Transcript

Surgery Partners reported Q1 net revenue of $811 million and adjusted EBITDA of $102 million, both in line with expectations, with same-facility revenue growth of 4.4% and margin at 12.6%. Operating cash flow doubled to $12 million, while cost ratios improved despite roughly $7 million of higher interest expense, $2 million of quarterly provider-tax/Medicaid headwinds, and weather-related case deferrals that trimmed growth by about 40 bps. Management reiterated full-year guidance of $3.35 billion-$3.45 billion revenue and at least $530 million adjusted EBITDA, and confirmed ongoing portfolio optimization and M&A pipeline activity.

Analysis

The setup is more interesting than the headline numbers suggest: this is a margin-repair story with a lag. Management is explicitly telegraphing that the first quarter was the trough for several temporary drags, while the second half should benefit from normalized staffing incentives, easing interest drag, and operating leverage from a better case mix. That makes the next two quarters the key inflection window; if the expected H2 acceleration does not show up, the market will likely conclude that the earnings algorithm is permanently lower rather than merely delayed.

The biggest second-order winner is not Surgery Partners itself but the physician-partnership model and adjacent outpatient equipment vendors. Robotics penetration and MSK-heavy de novos create a flywheel: higher-acuity cases justify technology spend, which pulls in physicians, which supports more joint volume and higher commercial mix. The flip side is that this also increases exposure to procedural utilization scrutiny and payer tactics; any tightening in prior auth or reimbursement on joints and vascular could hit the very specialties driving the growth mix.

Contrarian takeaway: consensus may be underestimating how much of the current margin pressure is self-inflicted and reversible versus structural. The provider-tax and swap-related hits are finite, while DSO stabilization at 66 days leaves a clear cash conversion lever if facility-level discipline improves. If management executes on even part of the $200M capital-deployment target and a midyear portfolio transaction, the equity can rerate quickly on deleveraging optionality rather than just operating earnings.

The primary risk is timing, not thesis: weather helped create an easy excuse in Q1, but the market will care about whether Q2 EBITDA beats the low end of the guide and whether cash flow inflects. A miss there would pressure the stock because leverage is still elevated and buybacks are inactive, limiting near-term capital return support. The stock likely trades best as a 3-6 month catalyst basket around portfolio optimization, not as a passive long if execution remains uneven.

Key Decisions for Investors

• Go long SGRY on a 3-6 month horizon ahead of the mid-2026 portfolio-optimization catalyst; target a re-rating if H2 margin recovery and deleveraging begin to show through. Risk/reward is attractive if the market starts capitalizing normalized EBITDA instead of current run-rate pressure.
• Use a call spread in SGRY (e.g., 6-9 month tenor) to express upside into Q2/Q3 while limiting downside from leverage and timing risk. Best entry is on any post-earnings pullback if guidance is maintained but the market overreacts to Q2 seasonality.
• Pair trade: long SGRY / short a higher-multiple hospital operator with weaker outpatient leverage, on the view that ASC migration and robotics create a more durable case-mix tailwind for SGRY. This isolates execution versus sector beta and benefits if outpatient share gains continue.
• Short-dated hedge: buy downside protection around the next earnings print if the stock rallies into the call, since Q2 guide implies seasonality plus normalization could compress near-term upside. The key risk is that the market is pricing H2 execution too early.
• Watch for confirmation in quarterly DSO and same-facility revenue per case; if both improve sequentially, add to longs. If DSO stays stuck and case growth remains sub-1%, treat the name as a value trap and cut exposure.